New combo therapy aims to beat back tough lymphoma

NCT ID NCT04484012

Recruiting now Disease control Sponsor: City of Hope Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests a combination of two treatments for mantle cell lymphoma that has returned or is not responding to standard care. Patients receive their own immune cells that have been genetically modified to recognize and attack cancer cells (CAR-T cells), along with a daily pill called acalabrutinib that blocks cancer growth signals. The study will enroll 36 participants to see if the combination is safe and how many patients achieve a complete response within 6 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CAR-T cells (engineered immune cells) and acalabrutinib (a targeted cancer pill)
What this could lead to: If successful, this combination could offer a new treatment option for patients with mantle cell lymphoma that has come back or stopped responding to other therapies.
What could go wrong: This is a small, early-phase trial (36 people) focused on safety and initial effectiveness. The treatment may cause serious side effects, and it is not yet known if it works better than existing options.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT MANTLE CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

mantle cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT MANTLE CELL LYMPHOMA REFRACTORY MANTLE CELL LYMPHOMA

Contacts and locations

Locations

City of Hope Comprehensive Cancer Center
RECRUITING

Duarte, California, 91010, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.